Treatment of Actinic Cheilitis Using a 1,927-nm Thulium Fractional Laser

Ghasri, Pedram; Admani, Shehla; Petelin, Anthony; Zachary, Christopher B.

doi:10.1111/j.1524-4725.2011.02262.x

Cited by 16 publications

(7 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The wavelengths of a thulium fiber laser (1927 nm) have a high absorption coefficient in water [22] that leads to a relatively shallow penetration depth up to 200 µm from the tissue surface [23]. Therefore, it is widely used for superficial skin rejuvenation [24][25][26]. In our study with two strains of syngeneic tumor mice (i.e.…”

Section: Discussionmentioning

confidence: 99%

Non-ablative Fractional Thulium Laser Irradiation Suppresses Early Tumor Growth

Yoo

Park

et al. 2017

Current Optics and Photonics

View full text Add to dashboard Cite

In addition to its typical use for skin rejuvenation, fractional laser irradiation of early cancerous lesions may reduce the risk of tumor development as a byproduct of wound healing in the stroma after the controlled injury. While fractional ablative lasers are commonly used for cosmetic/aesthetic purposes (e.g., photorejuvenation, hair removal, and scar reduction), we propose a novel use of such laser treatments as a stromal treatment to delay tumorigenesis and suppress carcinogenesis. In this study, we found that non-ablative fractional laser (NAFL) irradiation may have a possible suppressive effect on early tumor growth in syngeneic mouse tumor models. We included two syngeneic mouse tumor models in irradiation groups and control groups. In the irradiation group, a thulium fiber based NAFL at 1927 nm was used to irradiate the skin area including the tumor injection region with 70 mJ/spot, while no laser irradiation was applied to the control group. Numerical simulation with the same experimental condition showed that thermal damage was confined only to the irradiation spots, sparing the adjacent tissue area. The irradiation groups of both tumor models showed smaller tumor volumes than the control group at an early tumor growth stage. We also detected elevated inflammatory cytokine levels a day after the NAFL irradiation. NAFL treatment of the stromal tissue could potentially be an alternative anticancer therapeutic modality for early tumorigenesis in a minimally invasive manner.

show abstract

Section: Discussionmentioning

confidence: 99%

Non-ablative Fractional Thulium Laser Irradiation Suppresses Early Tumor Growth

Yoo

Park

et al. 2017

Current Optics and Photonics

View full text Add to dashboard Cite

show abstract

“…Epithelial–mesenchymal transition (EMT) is a process by which epithelial cells lose their polarity and are converted to a mesenchymal phenotype. It has been suggested as a pivotal step for cancer invasion and metastasis [12, 13]. Activation of EMT is related to aberrant expression of a variety of genes.…”

Section: Introductionmentioning

confidence: 99%

Inhibition of miR-9-5p suppresses prostate cancer progress by targeting StarD13

Chen

et al. 2019

Cell Mol Biol Lett

View full text Add to dashboard Cite

Background This study aims to investigate the effects of inhibiting microRNA-9-5p (miR-9-5p) on the expression of StAR-related lipid transfer domain containing 13 (StarD13) and the progress of prostate cancer. Methods The mRNA expression levels of miR-9-5p and StarD13 were determined in several prostate cancer cell lines. We chose DU145 and PC-3 cells for further research. The CCK8 assay was used to measure the cell viability. The cell invasion and wound-healing assays were respectively applied to evaluate invasion and migration. The expression of E-cadherin (E-cad), N-cadherin (N-cad) and vimentin were measured via western blot. DU145 and PC-3 cells overexpressing StarD13 were generated to investigate the variation in proliferation, invasion and migration. A luciferase reporter assay was used to identify the target of miR-9-5p. Results Our results show that miR-9-5p was highly expressed and StarD13 was suppressed in prostate cancer cells. MiR-9-5p inhibition repressed the cells’ viability, invasion and migration. It also increased the expression of E-cad and decreased that of N-cad and vimentin. StarD13 overexpression gave the same results as silencing of miR-9-5p: suppression of cell proliferation, invasion and migration. The bioinformatics analysis predicted StarD13 as a target gene of miR-9-5p. Quantitative RT-PCR, western blot analysis and the dual-luciferase reporter assay were employed to confirm the prediction. Conclusion Our results show that miR-9-5p plays a powerful role in the growth, invasion, migration and epithelial–mesenchymal transition (EMT) of prostate cancer cells by regulating StarD13. A therapeutic agent inhibiting miR-9-5p could act as a tumor suppressor for prostate cancer.

show abstract

“…Ten studies were included in this review and processed for data extraction (Table ). Thirty‐eight full texts were excluded for the following reasons: case report or fewer than 10 cases (Chakrabarty, Mraz, Geisse, & Anderson, ; Ghasri, Admani, Petelin, & Zachary, ; McDonald, Laverick, Fleming, & White, ; Rossi, Assad, Buggiani, & Lotti, ); follow‐up of <6 months or not specified (Alexiades‐Armenakas & Geronemus, ; Armenores, James, Walker, & Huilgol, ; Berking et al, ; Calzavara‐Pinton, Rossi, Sala, & Italian Group For Photodynamic Therapy, ; Chaves et al, ; de Godoy Peres, Aigotti Haberbeck Brandão, Rodarte Carvalho, Dória Filho, & Plapler, ; Kim, Song, & Kim, ; Menta Simonsen Nico, Rivitti, & Lourenço, ; Menta Ulrich et al, ; Ribeiro et al, ; Spyridonos, Gaitanis, Tzaphlidou, & Bassukas, ; Ulrich et al, ); abstract, comment, or literature review (Alexiades−Armenakas, ; Dinani, Topham, Derrick, & Atkinson, ; Goldman, ; Kuwahara & Rasberry, ; Larios, Alevizos, & Rigopoulos, ; Laws, Wilde, & Grabski, ); insufficient data regarding treatment, lesion location, or outcome (Jorizzo, Weiss, & Vamvakias, ; Nelson et al., 2007; Ntomouchtsis et al, ; Rossoe, Tebcherani, Sittart, & Pires, ; Sand, Altmeyer, & Bechara, ; Sotiriou, Apalla, Koussidou, & Ioannides, ; Stough, Bucko, Vamvakias, Rafal, & Davis, ); studies including patients with a previous diagnosis of SCC or those with SCC in the sample (Dufresne, Cruz, Zeikus, Perlis, & Jellinek, ; Laws et al, ; Smith, Germain, Yeager, & Skelton, ; Zaiac & Clement, ); and articles that were not in English (Ceylan, Erboz, Özdemir, & Kazandi, ; Ceylan, Özdemir, & Kazandi, ; Ulrich et al., ).…”

Section: Resultsmentioning

confidence: 99%